One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
September 12, 2024 16:05 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, in collaboration with lead researchers at...
Noom Introduces Industry-First $149 Compounded GLP-1 with a Taper-Off Guarantee, Offering a Sustainable Approach to Long-Term Weight Loss
September 12, 2024 08:03 ET
|
Noom Inc
Noom will offer compounded GLP-1 injections paired with Noom’s powerful GLP-1 companion program, providing a sustainable pathway off the medications.
Acasti to Present at the Life Sciences Investor Forum
September 12, 2024 08:00 ET
|
Acasti Pharma, Inc.
PRINCETON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of...
KFSHRC Leads in Infectious Disease Diagnostics with Advanced Genomic Technologies
September 12, 2024 04:21 ET
|
King Faisal Specialist Hospital & Research Centre
KFSHRC Leads in Infectious Disease Diagnostics with Advanced Genomic Technologies
KFSHRC Announced a Strategic Partner for 2024 NYC C3 Summit Davos of Healthcare
September 11, 2024 10:16 ET
|
King Faisal Specialist Hospital & Research Centre
KFSHRC Announced a Strategic Partner for 2024 NYC C3 Summit Davos of Healthcare
Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024 10:35 ET
|
Acasti Pharma, Inc.
PRINCETON, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of...
Olon Continues its Growth Path and Announces a New Acquisition
September 04, 2024 05:00 ET
|
Olon SpA
MILAN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The acquisition plan involves a complete operational integration of Huvepharma Italia Srl and a plan to revive the production potential of the Garessio...
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
September 03, 2024 07:30 ET
|
23andMe, Inc.
Preliminary data from renal cancer and TMB-H/MSI-H cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented Analysis of CD200 as an exploratory tissue-based biomarker associated with...
KFSHRC Concludes Participation at AMEE 2024 in Switzerland
August 29, 2024 02:56 ET
|
King Faisal Specialist Hospital & Research Centre
KFSHRC Concludes Participation at AMEE 2024 in Switzerland
KFSHRC Sets New Global Standards with VR Technology at AMEE 2024
August 22, 2024 11:17 ET
|
King Faisal Specialist Hospital & Research Centre
KFSHRC Sets New Global Standards with VR Technology at AMEE 2024